Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIW 8962

Drug Profile

BIW 8962

Alternative Names: Anti-GM2 humanised antibody - Kyowa Kirin; BIW-8962

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin; Kyowa Hakko Kirin Korea
  • Developer BioWa; Kyowa Hakko Kirin Korea
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; G(M2) ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Oct 2016 Discontinued - Phase-II for Mesothelioma (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
  • 21 Oct 2016 Discontinued - Phase-II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top